Stock Track | Impact Therapeutics-B Plummets 5.18% Intraday on Post-IPO Profit-Taking and Weak Fundamentals

Stock Track

05/21

Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.

The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics listed on the Hong Kong Stock Exchange earlier this month, with its public offering oversubscribed by 2,282.4 times and surging 108.26% on the first day. Since then, the stock has retreated over 15% from its post-listing high as early investors lock in gains.

Fundamentally, the company remains in a loss-making phase, reporting a net loss of approximately RMB 296 million for 2025 on revenue of only RMB 38.25 million, insufficient to cover its intensive R&D expenditures. This limited fundamental support for its elevated valuation appears to be compounding selling pressure.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1116682247"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116682247\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116682247?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 10:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116682247","market":"hk","top_or_hot":-1,"title":"Stock Track | Impact Therapeutics-B Plummets 5.18% Intraday on Post-IPO Profit-Taking and Weak Fundamentals","media":"Stock Track","content":"<p>Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.</p><p>The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics listed on the Hong Kong Stock Exchange earlier this month, with its public offering oversubscribed by 2,282.4 times and surging 108.26% on the first day. Since then, the stock has retreated over 15% from its post-listing high as early investors lock in gains.</p><p>Fundamentally, the company remains in a loss-making phase, reporting a net loss of approximately RMB 296 million for 2025 on revenue of only RMB 38.25 million, insufficient to cover its intensive R&D expenditures. This limited fundamental support for its elevated valuation appears to be compounding selling pressure.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Impact Therapeutics-B Plummets 5.18% Intraday on Post-IPO Profit-Taking and Weak Fundamentals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Impact Therapeutics-B Plummets 5.18% Intraday on Post-IPO Profit-Taking and Weak Fundamentals\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-05-21 10:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.</p><p>The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics listed on the Hong Kong Stock Exchange earlier this month, with its public offering oversubscribed by 2,282.4 times and surging 108.26% on the first day. Since then, the stock has retreated over 15% from its post-listing high as early investors lock in gains.</p><p>Fundamentally, the company remains in a loss-making phase, reporting a net loss of approximately RMB 296 million for 2025 on revenue of only RMB 38.25 million, insufficient to cover its intensive R&D expenditures. This limited fundamental support for its elevated valuation appears to be compounding selling pressure.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07630","symbol_name":"英派藥業-B","start_time":0,"source_url":"","article_id":"1116682247","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116682247","pubTimestamp":1779330773,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"07630":"英派药业-B"},"translate_title":"个股追踪|Impact Therapeutics-B盘中暴跌5.18%受IPO后获利了结及基本面疲弱影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"07630":1},"content_text":"Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics listed on the Hong Kong Stock Exchange earlier this month, with its public offering oversubscribed by 2,282.4 times and surging 108.26% on the first day. Since then, the stock has retreated over 15% from its post-listing high as early investors lock in gains.Fundamentally, the company remains in a loss-making phase, reporting a net loss of approximately RMB 296 million for 2025 on revenue of only RMB 38.25 million, insufficient to cover its intensive R&D expenditures. This limited fundamental support for its elevated valuation appears to be compounding selling pressure.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}